Used in the treatment of tuberculosis, this compound is a key component of first-line anti-TB therapy. It works effectively against dormant Mycobacterium tuberculosis bacteria, especially in acidic environments such as those found within macrophages. Its main role is to shorten the duration of treatment in combination regimens, making it essential in directly observed therapy short-course (DOTS) programs. It is particularly active during the initial intensive phase of treatment, helping to reduce the bacterial load quickly. Due to its unique mechanism of action, it contributes to preventing relapse and the development of drug resistance when used with other antituberculosis agents like isoniazid and rifampicin.